Conference Coverage (Hepatitis)

Candidate HBV Vaccine Includes preS1 Sequences

Published in Virus Weekly, February 9th, 1998

A highly immunogenic hepatitis B virus candidate vaccine using particulate recombinant large antigen PreS1 is under development by Australia's Immuno/Baxter Biomedical Research.

The problem of non-responsiveness to current hepatitis B virus (HBV) vaccines containing recombinant small antigen (r-sAg) from engineered yeast cells is overcome by preS sequences present in the HBV preS2 or middle (preS2-sAg) surface glycoprotein and in the HBV preS1 or large (preS1-preS2-sAg) surface glycoprotein.

Third generation recombinant HBV vaccines including preS sequences are not yet commercially available.

"Several reasons may account for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Virus Weekly

Source: Virus Weekly (1998-02-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry